Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1052837/000104746905006618/a2153526z10-k.htm
March 2006
February 2006
December 2005
December 2005
December 2005
November 2005
October 2005
September 2005
August 2005
July 2005
Exhibit 99.1
FOR IMMEDIATE RELEASE |
NEWS |
Contact: |
Ami Knoefler |
|
Senior Director |
|
Corporate Communications and Investor Relations |
|
510-284-6350 or 510-284-6605 |
ABGENIX ANNOUNCES 2004 FOURTH QUARTER AND FULL YEAR
FINANCIAL RESULTS
FREMONT, Calif., February 22, 2005 - Abgenix, Inc. (Nasdaq:ABGX) today reported financial results for the fourth quarter and full year ended December 31, 2004.
For the quarter ended December 31, 2004, the company reported a net loss of $42.9 million or $0.48 per share, compared to a net loss of $53.0 million or $0.60 per share for the same period in 2003. The net loss for the fourth quarter of 2003 included a $7.9 million impairment charge related to an investment. The company ended 2004 with $416.3 million in cash, cash equivalents and marketable securities.
Revenues for the fourth quarter of 2004 were $5.9 million, compared to $6.4 million for the same period in 2003. Contract revenues for the quarter ended December 31, 2004 primarily consisted of milestones and fees from technology licensing agreements, including milestones from Human Genome Sciences, Chiron and CuraGen for advancing XenoMouse®-derived antibodies into the clinical phase. The companys revenues typically result from milestone payments and fees associated with various collaborations and technology licensing agreements.
Operating expenses for the fourth quarter of 2004 were $47.2 million, compared to $51.8 million for the same period in 2003. The majority of fourth quarter 2004 research and development costs related to advancement of the companys proprietary clinical product candidates, including its lead oncology product candidate, panitumumab, and ABX-PTH, an antibody for secondary hyperparathyroidism (SHPT). Included in both periods were manufacturing start-up costs related to operating the companys antibody production facility. A portion of the costs associated with this facility will continue to be classified as manufacturing start-up costs until the facility is operating at normal capacity.
-more-
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1052837/000104746905006618/a2153526z10-k.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Abgenix Inc.
Abgenix Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2005 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Abgenix Inc provided additional information to their SEC Filing as exhibits
CIK: 1052837
Form Type: 10-K Annual Report
Accession Number: 0001047469-05-006618
Submitted to the SEC: Tue Mar 15 2005 7:57:36 PM EST
Accepted by the SEC: Wed Mar 16 2005
Period: Friday, December 31, 2004
Industry: Biological Products No Disgnostic Substances